Effect of teriflunomide on QuantiFERON-TB Gold results
Effect of teriflunomide on QuantiFERON-TB Gold results
复制标题
DOI：
10.1007/s00430-016-0482-x
复制
发表时间：
2017-02-01
影响因子：
5.4
通讯作者：
Molicotti, Paola
中科院分区：
文献类型：
--
作者：
Bua, Alessandra;Ruggeri, Melania;Molicotti, Paola
多发性硬化症是一种中枢神经系统慢性炎症性疾病，以髓鞘和轴突损伤为特征，随着时间的推移导致进行性神经元变性和小胶质细胞活化。目前仍没有治愈性治疗，但在过去20年中，已有8种不同的治疗方法可用，包括干扰素β、醋酸格拉替雷默、特利氟米特、富马酸二甲酯、那他珠单抗、fingolimod、阿仑单抗、米托蒽醌和特利氟米特。特立氟米特是一种免疫调节药物，对多发性硬化症患者中枢神经系统T细胞活化有抑制作用。我们通过QuantiFERON-TB试管试验确定了特立氟米特是否影响干扰素- γ、白细胞介素-2和肿瘤坏死因子- α的产生。将24名潜伏性结核感染成人的血液加入一组QuantiFERON标准管和另一组含有特立氟米特的管中。泰瑞氟米特导致四名患者的QuantiFERON结果从阳性变为阴性，干扰素- γ显著降低。我们的数据表明，在接受特立氟米特治疗的患者中使用QuantiFERON的结果应谨慎解释。
Multiple sclerosis is a chronic inflammatory disease of the central nervous system characterized by damage to myelin and axons, over time leading to progressive neuronal degeneration and microglial activation. There is still no curative treatment, but during the last 20 years eight different therapies have become available including interferon beta, glatiramer acetate, teriflunomide, dimethyl fumarate, natalizumab, fingolimod, alemtuzumab, mitoxantrone and teriflunomide. Teriflunomide is an immunomodulatory drug that exerts an inhibitory effect on T cell activation in central nervous system of the patients with multiple sclerosis. We determined whether teriflunomide affect the production of interferon-gamma, interleukin-2 and tumor-necrosis-factor-alpha in the QuantiFERON-TB in-Tube-assay. Blood from 24 adults with latent tuberculosis infection was added to one standard set of QuantiFERON tubes and one further set containing teriflunomide. Teriflunomide resulted in a change in QuantiFERON results from positive to negative in four patients with a marked reduction in interferon-gamma. Our data indicated that results from QuantiFERON in patients on teriflunomide therapy should be interpreted with caution.